Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1664 |
Name | pineoblastoma |
Definition | A pineal gland neoplasm located_in the brain. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pineal gland cancer pineoblastoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00602667 | Phase I | Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Cyclophosphamide + Etoposide + Topotecan Cyclophosphamide + Erlotinib + Topotecan | Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma | Active, not recruiting | USA | AUS | 0 |
NCT00983398 | Phase Ib/II | Pegfilgrastim Filgrastim Carboplatin + Melphalan | Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors | Unknown status | USA | 0 |
NCT01217437 | Phase II | Irinotecan + Temozolomide Bevacizumab + Irinotecan + Temozolomide | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors | Completed | USA | NZL | CAN | AUS | 1 |
NCT02095132 | Phase Ib/II | Adavosertib + Irinotecan | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT02596828 | Phase II | Dasatinib + Irinotecan + Sirolimus + Temozolomide | Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma | Completed | DEU | 0 |
NCT03173950 | Phase II | Nivolumab | Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers | Recruiting | USA | 0 |
NCT05064306 | Expanded access | Omburtamab I-131 | 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults | Available | USA | 0 |